Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) is soliciting applications to support research on HIV cure in pediatric populations. This FOA will support coordinated basic, clinical, and applied research focused on developing strategies to achieve an HIV cure, defined as either sustained viral remission or eradication of HIV infection. The cure of HIV infection in people living with HIV is one of the highest priorities of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The goal of the Martin Delaney Collaboratory program is to accelerate progress towards developing strategies to achieve either eradication of HIV infection from the body or a sustained viral remission, as defined by sustained viral suppression following cessation of antiretroviral therapy. Funded projects under this FOA will be expected to expand the knowledge base on HIV latency and persistence in pediatric populations, design and evaluate innovative cure strategies, develop and evaluate assays and other modalities to accurately characterize HIV reservoirs and translate findings to the clinical settings. This funding opportunity will target perinatally infected children and adolescents and young adults up to 24 years of age with a primary focus on early treated children.

Application Instructions

Please submit:

1. a one-page letter of intent with a description of proposed aims and approach
2. CV (not NIH format)  of the PI

to research@uw.edu by 5:00 PM Thursday September 24, 2020. Proposals are due to the 12/7/20, so you will need to have your materials in to the Office of Sponsored Programs by 11/25/20 for processing, if given the go ahead by the Proposal Review Committee.